The Latest Cardiac and Vascular News
HALETHORPE, Md., Sept. 24, 2024 /PRNewswire/ — Fzata, Inc. is pleased to announce a five-year UG3/UH3 non-dilutive grant (UG3NS135350) of up to $7 million, plus in-kind contributions, awarded by the NIH National Institute of Neurological Disorders and Stroke (NINDS). Grant participants…
Shocking Increase in Heart Failure Prevalence, Mortality, and Impact on Younger Patients WASHINGTON, Sept. 24, 2024 /PRNewswire/ — The latest findings on heart failure (HF) published by Heart Failure Society of America (HFSA) reveal a concerning rise in the prevalence, mortality, and…
PROVIDENCE, R.I., Sept. 24, 2024 /PRNewswire/ — Findings from a new systematic review, titled “Chest Pain in Primary Care: A Systematic Review of Risk Stratification Tools to Rule Out Acute Coronary Syndrome,” published in Annals of Family Medicine, suggest that high-sensitivity troponin…
-BLA to be Supported by Existing and Natural History Cardiac Data as Discussed with the FDA-
CHELMSFORD, Mass.–(BUSINESS WIRE)–ZOLL®, an Asahi Kasei company that manufactures medical devices and related software solutions, announced today that the first patient has been enrolled in the SuperSaturated oxygen Comprehensive Observational REgistry (SSCORE). The prospective study is designed to provide further evidence of the efficacy of SuperSaturated Oxygen (SSO2) Therapy to reduce heart failure and […]
Funds from Novo Holdings will support global commercial expansion Novo Holdings’ Noel Jee joins Route 92 Board of Directors SAN MATEO, Calif., Sept. 23, 2024 (GLOBE NEWSWIRE) — Route 92 Medical, Inc., a privately held medical technology company dedicated to improving outcomes for patients undergoing neurovascular intervention, today announced a […]
Korean nationwide cohort study shows increased complications for both mothers and newborns in deliveries following uterine artery embolization SEOUL, South Korea, Sept. 23, 2024 /PRNewswire/ — Postpartum hemorrhage (PPH) is a serious condition where a woman experiences significant blood…
– New data from the HuMAIN study, which met the primary endpoint of weight loss and several efficacy and pharmacodynamic secondary endpoints, will be presented in a Late Breaking Clinical Research Session – – HU6, a novel oral, once-daily Controlled Metabolic Accelerator, is a new class…
BEIJING, Sept. 23, 2024 /PRNewswire/ — Professor Luo Min, from Beijing Yuhe Integrated Traditional Chinese and Western Medicine Rehabilitation Hospital, has been invited to attend the 36th World Congress on Cardiology and Heart Disease on October 17-18, 2024 in London to introduce his…
NEW DELHI, Sept. 21, 2024 /PRNewswire/ — Translumina was incorporated in 2011 as a sales & marketing company specialising in coronary intervention devices. Since its inception, the company has successfully established their own manufacturing capabilities and developed in-house product…
